3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow TenNor Therapeutics Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092 [14C]-TNP-2092 - Healthy | Phase 1 | Completed | TenNor Therapeutics Limited | 6 | 2021-10-16 | 2022-10-19 |
| Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty TNP-2092 - Prosthetic Joint Infection | Phase 1 | Completed | TenNor Therapeutics Limited | 13 | 2021-03-01 | 2022-10-19 |
| TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection TNP-2092, Vancomycin - Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections | Phase 2 | Completed | TenNor Therapeutics Limited | 120 | 2019-04-20 | 2023-12-01 |
Gram-Positive Bacterial Infections (1)
TNP-2092 (2) · CBR 2092 (1) · Vancomycin (1)
United States (3)